Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations

Advanced gastrointestinal stromal tumors (GIST), a KIT oncogene-driven tumor, on imatinib mesylate (IM) treatment may develop secondary KIT mutations to confer IM-resistant phenotype. Second-line sunitinib malate (SU) therapy is largely ineffective for IM-resistant GISTs with secondary exon 17 (acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsueh, Yuan-Shuo, Lin, Chih-Lung, Chiang, Nai-Jung, Yen, Chueh-Chuan, Li, Chien-Feng, Shan, Yan-Shen, Ko, Ching-Huai, Shih, Neng-Yao, Wang, Ling-Mei, Chen, Ting-Shou, Chen, Li-Tzong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688691/
https://www.ncbi.nlm.nih.gov/pubmed/23840364
http://dx.doi.org/10.1371/journal.pone.0065762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688691/
https://www.ncbi.nlm.nih.gov/pubmed/23840364
http://dx.doi.org/10.1371/journal.pone.0065762

Ejemplares similares